Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress

Published

on

62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker negative patients using the Xerna™ TME Panel

9.2 month vs. 3.9 month median progression free survival in biomarker positive vs. biomarker negative patients using the Xerna TME Panel

WALTHAM, Mass., Oct. 23, 2021 (GLOBE NEWSWIRE) — OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced new biomarker data from a retrospective analysis of results from its Phase 1b clinical trial of navicixizumab in an electronic poster at the European Society of Gynaecological Oncology (ESGO) Congress 2021.

Data presented in the poster are from a retrospective analysis of results from an open-label Phase 1b trial evaluating navicixizumab, a potentially first-in-class anti-DLL4/VEGF bispecific antibody targeting tumor vasculature, in combination with paclitaxel in patients with platinum-resistant ovarian cancer (PROC). Pre-treatment biopsies were analyzed using the investigational Xerna TME Panel to retrospectively compare the biomarker classification of patients against clinical outcomes.

“There is a pressing unmet need for new treatments for patients with platinum-resistant ovarian cancer who have progressed on Avastin® or failed more than two lines of prior therapy,” said Dr. Kathleen Moore, Stephenson Cancer Center, Oklahoma. “I believe the data presented at ESGO demonstrated the potential of navicixizumab together with the Xerna TME Panel to help address this need. The response rate and treatment durability of navicixizumab in this heavily pretreated patient population are very exciting and results showed improved outcomes in patients classified as having a high angiogenesis score by the Xerna TME Panel’s novel, RNA-expression based algorithm. We have been searching for a predictive biomarker for anti-angiogenic therapies and the Xerna TME panel results presented at ESGO are very promising.”

Key data and conclusions from the ESGO poster include:

  • Clinical outcomes were greater in biomarker positive (B+) vs. biomarker negative (B-) patients
    • Overall response rate (ORR) in B+ patients: 62% (8/13)
    • ORR in B- patients: 25% (5/20)
    • ORR across all patients: 43% (19/44)
    • Disease control rate (DCR) in B+ patients: 100% (13/13)
    • DCR in B- patients: 65% (13/20)
    • DCR across all patients: 77% (34/44)
  • A consistent correlation was seen between B+ subtype and improved progression-free survival (PFS)
    • Median PFS in B+ patients: 9.2 months (95% confidence interval: 5.5 – not estimable)
    • Median PFS in B- patients: 3.9 months (95% confidence interval: 1.8 – 8.9)

Laura Benjamin, Ph.D., President and Chief Executive Officer of OncXerna, commented, “The retrospective biomarker analyses presented at ESGO provide an important point of validation for the development of the Xerna TME Panel. Our next step is to further explore these findings through a prospective Phase 3 trial of navicixizumab plus paclitaxel that is also designed to quantify the Xerna TME Panel’s predictive value. We look forward to the initiation of this trial and the evaluation of our Xerna TME Panel as a potential companion diagnostic for immuno-oncology and anti-angiogenic agents.”

A copy of the ESGO poster (Abstract 918), entitled: “Correlative analyses of a Phase 1b study of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian cancer using the Xerna TME Panel,” can be found here.

About the Phase 1b Trial

The Phase 1b trial was an open-label, non-randomized, dose-escalation and expansion study of the safety, tolerability, and efficacy of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian cancer. The trial enrolled patients who previously received Avastin (bevacizumab) and/or more than 2 prior lines of therapy. Patients were treated with navicixizumab once every two weeks together with weekly paclitaxel. The primary endpoint of the trial was incidence of dose limiting toxicities. Secondary endpoints included response rate assessed by RECIST criteria 1.1 and progression-free survival. For more information, see ClinicalTrials.gov Identifier: NCT03030287.

About Navicixizumab

Navicixizumab is an anti-DLL4/VEGF bispecific antibody product candidate that demonstrated antitumor activity in patients who were previously treated with Avastin® (bevacizumab) in a Phase 1b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal, or fallopian tube cancer in patients who have previously received Avastin and/or more than 2 prior lines of therapy. Navicixizumab is an investigational agent that has not been approved, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer. 

About the Xerna TME Panel

The Xerna TME Panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on the interplay between angiogenic and immunogenic dominant biologies of the tumor microenvironment (TME). The Xerna TME Panel is an investigational assay that has not been approved and has not been demonstrated to be safe or effective for any use.

About OncXerna Therapeutics

OncXerna is an oncology therapeutics company with an innovative precision medicine platform, the Xerna platform. The Xerna platform leverages artificial intelligence technologies to build RNA expression-based biomarker panels that capture the driving biology of an individual tumor in an effort to enable a diagnostic hypothesis for matching patients with drugs targeted to their particular tumor biology. Our current clinical pipeline and first Xerna Panel targets the tumor microenvironment. Our mission is to expand the reach of precision medicine beyond the limited options currently available to address the urgent needs of patients with cancer. By integrating our novel Xerna platform with our deep expertise in clinical development, we believe we can accelerate the development of our novel product candidates and bring meaningful new treatments to patients at an earlier point in time in their disease progression. For more information, please visit oncxerna.com, or follow us on LinkedIn and Twitter.

Investor and Media Contact:

Ashley R. Robinson
LifeSci Partners, LLC
[email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

The Channel Company Announces New Chief Revenue Officer Wayne Silverman

Published

on

the-channel-company-announces-new-chief-revenue-officer-wayne-silverman

WESTBOROUGH, Mass., April 16, 2024 /PRNewswire/ — The Channel Company, a global provider of news, insights, strategy, events, and marketing services for the information technology industry, announced today that Wayne Silverman has joined the executive team as Chief Revenue Officer. Silverman will lead all aspects of The Channel Company’s worldwide revenue growth initiatives, sales strategy innovation, and customer engagement.

Silverman joins The Channel Company most recently from Spiceworks Ziff Davis (SWZD), where he served as Chief Revenue Officer. He also brings more than 25 years of digital media, technology, SaaS, and big data experience within global roles. Silverman has driven revenue innovation and growth across prominent companies including CBS, Dun & Bradstreet, International Data Group (IDG), CNET, and Business.com where he held senior leadership positions. 
“We are thrilled to welcome Wayne to the team,” said Matthew Yorke, CEO of The Channel Company. “His global expertise within the technology and digital media industries alongside his unwavering dedication to customer experience will continue to elevate how we deliver for our clients and drive expanded opportunities for our organization.”
“It’s a privilege to step into the role of CRO at The Channel Company during such a pivotal period for the company,” Silverman stated. “As we look ahead, the tech sector is poised for a transformation with artificial intelligence taking center stage. The Channel Company, with its esteemed media outlets, signature events, and expert marketing and consulting offerings, will be instrumental for our partners, clients, and the entire tech community. I am eager to collaborate with the talented team here at The Channel Company to deliver innovative, outcome-driven services to our clients as this market evolves.”
About The Channel Company
The Channel Company, Inc. is the global leader in data-driven growth acceleration solutions and services for the IT channel. With 40+ years of channel expertise and a premier portfolio of editorial brands, marketing and event services, and strategic consulting, we help technology vendors, solution providers, and IT decision-makers worldwide unlock better business outcomes. The Channel Company is a portfolio company of investment funds managed by EagleTree Capital, a New York City-based private equity firm. For more information, visit thechannelco.com.   
About EagleTree Capital:
EagleTree Capital is a leading New York-based middle-market private equity firm, with over $5.6 billion of assets under management, that has completed over 40 private equity investments and over 95 add-on transactions over the past 20+ years. EagleTree primarily invests in North America in the following sectors: media and business services, consumer, and water and specialty industrial. For more information, visit www.eagletree.com or find EagleTree on LinkedIn.
Media contact: Corporate Communications, [email protected]
Logo – https://mma.prnewswire.com/media/2314377/The_Channel_Company_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/the-channel-company-announces-new-chief-revenue-officer-wayne-silverman-302118460.html

Continue Reading

Artificial Intelligence

vLex Launches Vastly Expanded Vincent Legal GenAI Toolset, and AI-Focused Co-Development Lab

Published

on

vlex-launches-vastly-expanded-vincent-legal-genai-toolset,-and-ai-focused-co-development-lab

Global Legal Intelligence Innovator Adds Litigation and Transactional GenAI Tools, and vLex Labs, an AI-Focused Co-Development Unit
MIAMI, April 16, 2024 /PRNewswire/ — Today legal intelligence innovator vLex launched a powerful suite of generative AI-backed document analysis tools for litigation and transactional practitioners to the Vincent AI platform. Vincent AI Document Analyze augments lawyers’ responses to legal documents, drawing from the world’s most comprehensive global library of legal information.

In addition, vLex now offers vLex Labs to select Vincent customers – enabling them to create proprietary AI-powered workflows with the help of a dedicated team.
These developments underscore vLex’s commitment to developing innovative legal research solutions that go beyond retrieval to revolutionize how legal professionals work.
“With Vincent AI, you no longer have to choose between innovative technology and comprehensive content,” said vLex CEO Lluís Faus. “Our platform offers a seamless integration of both, setting a new standard in efficiency, customization, and effectiveness across all legal practices.”
Vincent AI Document Analyze
Vincent AI Document Analyze offers customizable GenAI-backed workflows that enable legal professionals to interrogate legal documents and use Vincent’s legal analysis abilities to begin drafting strategic responses. Benefits include:
Rapid Analysis: Vincent summarizes documents, and compares law across jurisdictions, replacing hours of non-billable time in minutes.Rapid Response: Vincent analyzes claims, generates defenses, and anticipates counterarguments.Streamlined Contract Analysis: Vincent instantly carries out tasks such as identifying problematic clauses, and providing mitigation steps.All insights are linked to primary and secondary law materials in vLex’s global repository, enabling verification with one click.
The new document analysis feature can be used with documents from any region. Vincent AI’s research workflows are available to legal professionals in the US, the UK, Ireland, Spain, the EU, Singapore, Mexico, Chile, and Colombia, with New Zealand launching in May 2024.
vLex Labs
vLex also launched vLex Labs – an exclusive in-house service that provides Enterprise customers access to leading experts on legal AI, uniting industry leaders such as Fastcase, Docket Alarm, Justis, and NextChapter.
Leading the team will be Dan Hoadley, who recently joined vLex as Head of R&D. The team will have a global scope, and work with firms to co-develop custom workflows, prepare data, and more.
About vLex
vLex is a global legal intelligence platform that provides legal professionals with access to the most extensive collection of legal and regulatory information worldwide, all on one award-winning, AI-powered, platform. vLex includes the Fastcase, Docket Alarm and NextChapter brands, and is trusted by more than two million lawyers, researchers, government departments, and law schools in more than 200 jurisdictions. The 2023 merger with Fastcase furthered vLex’s commitment to developing AI-driven solutions for the world’s legal industry and delivering the world’s largest global law library of over one billion legal documents on a single platform. Get updates at https://vlex.com/press and on Twitter @vlex. 
Photo – https://mma.prnewswire.com/media/2386032/vLex.jpgLogo – https://mma.prnewswire.com/media/2248313/vLex_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/vlex-launches-vastly-expanded-vincent-legal-genai-toolset-and-ai-focused-co-development-lab-302116091.html

Continue Reading

Artificial Intelligence

Atomicwork Launches New Digital Workplace Experience Solution Powered by Cohere’s Enterprise AI Platform

Published

on

atomicwork-launches-new-digital-workplace-experience-solution-powered-by-cohere’s-enterprise-ai-platform

SAN FRANCISCO, April 16, 2024 /PRNewswire/ — Atomicwork, the leading provider of AI-powered IT service management for modern enterprises, has announced the launch of its new digital workplace experience solution in collaboration with Cohere, the leading enterprise AI platform, to help businesses accelerate their workspace productivity and IT support automation.

Atom AI, Atomicwork’s digital assistant, delivers intelligent and contextual solutions to employee support questions to enhance workplace support experience and boost IT teams’ productivity. The solution eliminates the need for end users to switch between different business applications to find information, and enables them to get instant help on modern collaboration tools like Microsoft Teams or Slack, fostering efficient and proactive support.
Key highlights of the launch include:
Advanced AI Automation: Built-in Atom AI skills that autonomously solve end to end IT support issues by understanding end users’ work context, delivering true self-service for employees while accelerating efficiency for IT teams.Enhanced Employee Productivity: Advanced enterprise knowledge and search capabilities across a host of business applications and internal knowledge bases, delivered in the flow of an employee’s work, to help them find the right information quickly, boosting employee productivity and experience.Seamless Enterprise IT Integration: Embedded iPaas in the Atomicwork platform enabling IT teams to seamlessly integrate business applications and internal services to deliver modern enterprise service management use cases while reducing IT integration complexity.Atomicwork’s launch of the digital workspace experience solution is powered by Cohere, and their most advanced and scalable large language model, Command R+. Purpose-built for real-world enterprise use cases, Command R+ along with Cohere’s Rerank model, enables Atomicwork to deliver Atom AI with high accuracy and performance.
Commenting on the launch of a digital workplace experience solution and the collaboration with Cohere, Vijay Rayapati, Atomicwork’s CEO, stated, “We want to empower IT leaders to transform their digital experience journey with our new solution. This strategic collaboration of Atomicwork with Cohere enables us to deliver advanced and secure enterprise AI capabilities for our clients to streamline business workflow automations.”
“We’re excited Atomicwork is using Cohere’s industry-leading Command R model family to power their new digital workplace experience solution. Atomicwork’s software has the potential to significantly boost productivity for enterprise IT teams. We look forward to seeing the real-world benefits leaders like Atomicwork develop with our technology to help transform the global IT sector with AI,” said Abhishek Sinha, VP of Product at Cohere.
“Cohere’s new Command-R+ model delivers state-of-the-art accuracy, while offering a remarkable 50% reduction in latency when compared to more expensive models. This powerful combination of performance and efficiency empowers our AI-first approach to unlock new possibilities and provide exceptional experiences for our customers,” said Kiran Darisi, CTO, Atomicwork.
About Atomicwork
Atomicwork is a digital workplace experience platform that aims to deliver modern service management to enterprises. The platform empowers businesses to deliver fast and scalable internal support for their employees and end users, thereby enhancing employee experience with enterprise efficiency. Seamlessly integrating with existing enterprise applications and internal IT systems, Atomicwork connects employees, internal processes, and business systems, enhancing efficiency in workplace support, service, and operations.
About Cohere
Cohere is the leading AI platform for enterprise. Its world-class AI is uniquely suited to the needs of business, unlocking unprecedented ease-of-use, accessibility, and data privacy. Cohere’s platform is cloud-agnostic, accessible through API as a managed service, and can be deployed on virtual private cloud (VPC) or even on-site to meet companies where their data is, offering the highest levels of flexibility and control. Founded by Google Brain alumni and a co-author of the seminal Transformer research paper, Cohere is on a mission to transform enterprises and their products with AI that unlocks a more intuitive way to generate, search, and summarize information than ever before.
Press contact
Sairam [email protected] 
Logo – https://mma.prnewswire.com/media/2388312/Atomicwork.jpg

View original content:https://www.prnewswire.co.uk/news-releases/atomicwork-launches-new-digital-workplace-experience-solution-powered-by-coheres-enterprise-ai-platform-302118032.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending